DE60213766D1 - Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion - Google Patents

Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion

Info

Publication number
DE60213766D1
DE60213766D1 DE60213766T DE60213766T DE60213766D1 DE 60213766 D1 DE60213766 D1 DE 60213766D1 DE 60213766 T DE60213766 T DE 60213766T DE 60213766 T DE60213766 T DE 60213766T DE 60213766 D1 DE60213766 D1 DE 60213766D1
Authority
DE
Germany
Prior art keywords
accelerated
medicament
manufacture
treatment
active agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60213766T
Other languages
English (en)
Other versions
DE60213766T2 (de
Inventor
Marc Bigaud
Volker Brinkmann
Tomasz Sablinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104438A external-priority patent/GB0104438D0/en
Priority claimed from GB0105000A external-priority patent/GB0105000D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE60213766D1 publication Critical patent/DE60213766D1/de
Application granted granted Critical
Publication of DE60213766T2 publication Critical patent/DE60213766T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60213766T 2001-02-22 2002-02-21 Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion Expired - Fee Related DE60213766T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0104438 2001-02-22
GB0104438A GB0104438D0 (en) 2001-02-22 2001-02-22 Organic compounds
GB0105000A GB0105000D0 (en) 2001-02-28 2001-02-28 Organic compounds
GB0105000 2001-02-28
PCT/EP2002/001860 WO2002067915A1 (en) 2001-02-22 2002-02-21 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Publications (2)

Publication Number Publication Date
DE60213766D1 true DE60213766D1 (de) 2006-09-21
DE60213766T2 DE60213766T2 (de) 2007-08-02

Family

ID=26245749

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213766T Expired - Fee Related DE60213766T2 (de) 2001-02-22 2002-02-21 Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion

Country Status (12)

Country Link
US (2) US20040087662A1 (de)
EP (1) EP1368015B1 (de)
JP (1) JP4318921B2 (de)
CN (1) CN100479814C (de)
AT (1) ATE335475T1 (de)
BR (1) BR0207434A (de)
CA (1) CA2435739A1 (de)
DE (1) DE60213766T2 (de)
ES (1) ES2267993T3 (de)
HK (1) HK1060855A1 (de)
PT (1) PT1368015E (de)
WO (1) WO2002067915A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1429845E (pt) * 2001-06-08 2009-06-15 Novartis Ag Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina
KR100836547B1 (ko) 2002-01-11 2008-06-10 상꾜 가부시키가이샤 아미노 알코올 유도체 또는 포스폰산 유도체 및 이들을함유하는 의약 조성물
WO2005079788A1 (ja) 2004-02-24 2005-09-01 Sankyo Company, Limited アミノアルコール化合物
PL1772145T3 (pl) * 2004-07-16 2011-08-31 Kyorin Seiyaku Kk Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym
PT2511262T (pt) * 2004-10-12 2017-03-30 Kyorin Seiyaku Kk Processo para a produção de cloridrato de 2-amino-2-[2-[4-(3- benziloxi-feniltio)-2-clorofenil[etil]-1,3-propanodiol
PT1932522E (pt) * 2005-10-07 2012-06-26 Kyorin Seiyaku Kk Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
NZ574012A (en) * 2006-08-08 2012-02-24 Kyorin Seiyaku Kk Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
CN101501049B (zh) * 2006-08-08 2013-04-24 杏林制药株式会社 氨基磷酸酯衍生物以及将它们作为有效成分的s1p受体调节剂
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928572A (en) * 1971-02-11 1975-12-23 Ayerst Mckenna & Harrison Myriocin and process of preparation
ATE172711T1 (de) * 1992-10-21 1998-11-15 Yoshitomi Pharmaceutical 2-amino-1, 3- propandiolverbindung und immunosuppressium
CA2213989C (en) * 1995-12-28 2007-05-29 Yoshitomi Pharmaceutical Industries Ltd. External preparation for topical administration
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
DK1002792T3 (da) * 1997-04-04 2004-11-22 Mitsubishi Pharma Corp 2-aminopropan-1,3-diolforbindelser, medicinsk anvendelse deraf og mellemprodukter til syntese af disse
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
PT1429845E (pt) * 2001-06-08 2009-06-15 Novartis Ag Tratamento ou profilaxia da rejeição de enxertos de células produtoras de insulina

Also Published As

Publication number Publication date
PT1368015E (pt) 2006-12-29
ES2267993T3 (es) 2007-03-16
US20040087662A1 (en) 2004-05-06
CN100479814C (zh) 2009-04-22
CN1492757A (zh) 2004-04-28
WO2002067915A1 (en) 2002-09-06
BR0207434A (pt) 2004-07-06
ATE335475T1 (de) 2006-09-15
CA2435739A1 (en) 2002-09-06
EP1368015B1 (de) 2006-08-09
JP4318921B2 (ja) 2009-08-26
JP2004527490A (ja) 2004-09-09
US20080015261A1 (en) 2008-01-17
HK1060855A1 (en) 2004-08-27
DE60213766T2 (de) 2007-08-02
EP1368015A1 (de) 2003-12-10

Similar Documents

Publication Publication Date Title
ATE539701T1 (de) Zusammengesetzte schlinge zur behandlung von inkontinenz
DE69937888D1 (de) Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
CO5221115A1 (es) Nuevos compuestos fungicidas
ATE446776T1 (de) Zusammensetzung zur gefässbeschichtung
ATE404229T1 (de) Körper zum erzeugen von knochenwachstum und/oder bindegewebe und verfahren zur herstellung solches körpers
EA200300845A1 (ru) Модифицированные антитела и способы применения
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
DE60235928D1 (de) Mittel zur Suppression von Transplantat-Abstossung
TW200714283A (en) Method and composition for treating peripheral vascular diseases
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
WO2004039248A3 (en) Repairing or replacing tissues or organs
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
DE60213766D1 (de) Verwendung von beschleunigten lymphozyten zielansteuernden wirkstoffen zur herstellung eines medikaments für die behandlung der verzögertern transplantat-funktion
ATE217889T1 (de) Humane antikörper gegen faktor ix/ixa
DE602004018547D1 (de) Herstellung von tacrolimus (fk-506) unter verwendung neuer streptomyces-spezies
BR0010314B1 (pt) solução aquosa de conservação de tecidos e órgãos.
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
ATE489963T1 (de) Chaperonin-10-immunosuppression
DE60312684D1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
ATE304846T1 (de) Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen
BR0316245A (pt) Atividade antimicrobiana de espécie de oxigênio reativo produtora de anticorpos
AR041728A1 (es) Composicion fungicida para controlar enfermedades del arroz con cascara
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee